The Gene and Drug Delivery Systems (GDD) study section considers grant applications focused on fundamental aspects of gene and drug delivery, including delivery vehicle development, targeting strategies, and biological barriers. Applications are typically focused on bioengineering principles and may not be hypothesis driven.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Delivery of nucleic acids, peptide/protein complexes, vaccines, genes, small molecules, antibiotics, theranostics and other drugs and biomaterials to biological targets.
- Delivery vehicles including plasmids, viruses, liposomes, micelles, vesicles, nanoparticles, biomaterials, and cells.
- Delivery strategies including electroporation, ultrasound, light, and ballistic methods.
- Study of the biological barriers to delivery (e.g., membrane, tissue, cellular, trafficking, physical).
- Studies of the interactions of delivery vehicles, devices, and/or payloads with the immune system.
Shared Interests and Overlaps
There are shared interests with Nanotechnology (NANO) in the area of nano-therapeutics. Applications focused on the synthesis, chemical properties, biodistribution, and toxicology of nanoparticle-based delivery platforms may be assigned to NANO. Applications that focus on viral vectors or biological delivery issues involving the use of nanoparticles may be assigned to GDD.
There are shared interests with Biomaterials and Biointerfaces (BMBI) in the area of gene and drug delivery. Applications that focus on biocompatibility of delivery vehicles or delivery from implants may be assigned to BMBI. Applications that focus more on the design and development of novel delivery vehicles, vectors, or payloads may be assigned to GDD.
There are shared interests with study sections having a neuroscience perspective. Applications that focus on the delivery to the brain, including strategies to cross the blood-brain barrier, may be assigned elsewhere (Drug Discovery for the Nervous System Study Section [DDNS]) and Cellular and Molecular Biology of Glia (CMBG)). Applications with a vision focus may be assigned to Bioengineering of Neuroscience, Vision and Low Vision Technologies (BNVT). Applications that focus on the bioengineering aspects of delivery and the barriers to delivery may be assigned to GDD.
There are shared interests with study sections developing anti-cancer therapeutics. Applications that focus on target identification, high-throughput screening, molecular mechanisms of cancer and chemoresistance, and translational studies may be assigned elsewhere (Cancer Immunopathology and Immunotherapy (CII), Drug Discovery and Molecular Pharmacology (DMP), and Developmental Therapeutics (DT)). Applications that focus more on the design and delivery of novel vehicles, vectors, or payloads may be assigned to GDD.
There are shared interests with Vaccines Against Microbial Diseases (VMD) in the area of adjuvant and vaccine development for the treatment of microbial disease. Applications that focus on immune function, host defense, and microbial pathogenesis may be assigned to VMD. Applications that focus on adjuvant and vaccine design and delivery may be assigned to GDD.